Zymeworks Price to Sales Ratio 2016-2021 | ZYME

Historical PS ratio values for Zymeworks (ZYME) over the last 10 years. The current P/S ratio for Zymeworks as of January 27, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Zymeworks P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-01-28 8.45 19.10
2021-09-30 29.04 $0.44 65.65
2021-06-30 34.69 $0.41 84.58
2021-03-31 31.58 $0.62 51.02
2020-12-31 47.26 $0.78 60.88
2020-09-30 46.58 $0.51 90.54
2020-06-30 36.07 $0.64 56.06
2020-03-31 35.47 $0.64 55.41
2019-12-31 45.46 $0.84 53.94
2019-09-30 24.80 $1.79 13.87
2019-06-30 22.00 $1.67 13.17
2019-03-31 16.18 $2.25 7.19
2018-12-31 14.68 $1.88 7.81
2018-09-30 15.70 $3.23 4.86
2018-06-30 14.78 $3.17 4.66
2018-03-31 12.02 $2.42 4.97
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.386B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88